Striking efficacy of treatment of adult relapsed or refractory lymphomas and pediatric relapsed acute lymphoblastic leukemia by CAR T cells specific to the abundant B-cell marker CD19 was confirmed by numerous clinical trials2,3. Here, CD19 is linked to acute lymphoblastic leukemia.